Drug Profile
Research programme: allergen vaccines - NIOX
Alternative Names: Allergen desensitisation - NIOX; Allergen immunotherapy - NIOXLatest Information Update: 29 Jun 2023
Price :
$50
*
At a glance
- Originator Circassia
- Developer NIOX
- Class Epitopes; Subunit vaccines
- Mechanism of Action Immunosuppressants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Hypersensitivity
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Allergy in United Kingdom (Intradermal, Injection)
- 30 Jul 2012 Preclinical development is ongoing for Hypersensitivity to birch pollen, & early research is ongoing for Hypersensitivity to Alternaria spp., Japanese cedar pollen & dog dander
- 20 Jul 2010 Preclinical development is ongoing in United Kingdom